Skip to content

A single center open-label uncontrolled study to investigate the PSA and tumor vascularization response rate of neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable prostate cancer.

A single center open-label uncontrolled study to investigate the PSA and tumor vascularization response rate of neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable prostate cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28891
Enrollment
30
Registered
2006-01-11
Start date
2006-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All patients with histological proven prostate cancer who are eligible for laparoscopic radical prostatectomy will be asked to participate in the BAY 43-9006 study.

Interventions

Sponsors

Academic Medical Center, University of Amsterdam. Department of Urology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients > 18 years; 2. ECOG =1(2); 3. Biopsy proven prostate cancer; 4. Candidate for a radical prostatectomy and fit for surgery; 5. Clinical stage T1 – T2 Nx-0 Mx-0; 6. Adequate bone marrow function; 7. Adequate liver function; 8. Adequate renal function; 9. Adequate coagulation; 10. Men and partners must have adequate barrier birth control before and during and for 1 week after the trial; 11. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY43- 9006; 2. History of cardiac disease congestive heart failure, cardiac arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension; 3. History of chronic hepatits B or C and HIV infection; 4. Patients with seizure disorders (requiring medication); 5. Patients with evidence or history of bleeding diathesis; 6. Other investigational drug therapy within 30 days; 7.;Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study; 8. Unable to swallow oral medication; 9. Tumour/ disease specific criteria: chronic diarrhoea, bowel obstruction, degree of malnutrition, malabsorption; 10. Major surgery within 4 weeks before screening.

Design outcomes

Secondary

MeasureTime frame
1. Toxicity by means of the remaining laboratory assessments; 2. Number and severity of AEs; 3. Number and severity of SAEs.

Primary

MeasureTime frame
1. Response rate by means of PSA; 2. Quantitative changes in perfusion as measured by means of static and dynamic contrast enhanced ultrasound and static and dynamic contrast enhanced MRI; 3. Micro vessel density (MVD) in biopsy and resected material.

Contacts

Public ContactS.A. Zaaijer

Academic medical Center (AMC) Department of Urology P.O. Box 22660

S.A.Zaaijer@amc.uva.nl+31 (0)20 5666030

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)